- Home
- FLYE vs AYTU Comparison
FLYE vs AYTU Comparison
Compare FLYE & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLYE | AYTU |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 27.4M |
| IPO Year | 2024 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FLYE | AYTU |
|---|---|---|
| Price | $1.91 | $2.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | ★ 3.3M | 24.7K |
| Earning Date | 04-21-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.82 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $19,063,357.00 | ★ $27,632,080.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 277.47 |
| 52 Week Low | $0.48 | $1.65 |
| 52 Week High | $21.80 | $3.07 |
Technical Indicators
Market Signals| Indicator | FLYE | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 52.78 | 44.61 |
| Support Level | $1.65 | $2.21 |
| Resistance Level | $2.39 | $2.32 |
| Average True Range (ATR) | 0.29 | 0.08 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 39.86 | 16.28 |
Price Performance
Historical ComparisonAbout FLYE Fly-E Group Inc.
Fly-E Group Inc is principally engaged in designing, installing, and selling smart electric motorcycles, electric bikes, electric scooters, and related accessories under the Fly E-Bike brand. The Company encourages the adoption of eco-friendly transportation for active lifestyles.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.